The interaction of 4-alkyl derivatives of 2,6,7-trioxa-1-phosphabicyclo [2,2,2] octanes with cyclic adenosine 3',5'-monophosphate phosphodiesterase, and with cyclic adenosine 3',5'-monophosphate binding proteins.
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D001665:Binding Sites / Q000187:drug effects; D001667:Binding, Competitive; D001643:Bridged Bicyclo Compounds / Q000378:metabolism / Q000494:pharmacology; D002110:Caffeine / Q000494:pharmacology; D002352:Carrier Proteins / Q000378:metabolism*; D002540:Cerebral Cortex / Q000201:enzymology; D000242:Cyclic AMP / Q000378:metabolism*; D066298:In Vitro Techniques; D007700:Kinetics; D009943:Organophosphorus Compounds / Q000378:metabolism / Q000494:pharmacology*; D010726:Phosphodiesterase Inhibitors; D011485:Protein Binding / Q000187:drug effects; D012756:Sheep; D013806:Theophylline / Q000494:pharmacology
D001643:Bridged Bicyclo Compounds; D002352:Carrier Proteins; D009943:Organophosphorus Compounds; D010726:Phosphodiesterase Inhibitors; D002110:Caffeine; D013806:Theophylline; D000242:Cyclic AMP; D015105:3',5'-Cyclic-AMP Phosphodiesterases